Who
Cindy Tahl
Officer
Company insider
Files Form 4 as: General Counsel and Secretary, Fate Therapeutics.
In numbers
- Trades disclosed
- 147
- Buys
- 0
- Sells
- 30
- Bought
- $0
- Sold
- $28.9M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 15 Oct 2015
- Last trade
- 4 Aug 2026
- Last filed
- 5 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Aug 2026filed 5 Aug 2026 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Sold | $95K38,800 at $2.46 | filing |
| 4 Aug 2026filed 5 Aug 2026 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Sold | $95K38,800 at $2.46 | filing |
| 20 May 2026filed 21 May 2026 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Sold | $48K25,590 at $1.88 | filing |
| 20 May 2026filed 21 May 2026 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Sold | $48K25,590 at $1.88 | filing |
| 6 May 2026filed 7 May 2026 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Code M | $161K122,220 at $1.32 | filing |
| 6 May 2026filed 7 May 2026 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Code M | $47K44,444 at $1.05 | filing |
| 6 May 2026filed 7 May 2026 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —122,220 at $0.00 | filing |
| 6 May 2026filed 7 May 2026 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —122,220 at $0.00 | filing |
| 6 May 2026filed 7 May 2026 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —44,444 at $0.00 | filing |
| 6 May 2026filed 7 May 2026 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —44,444 at $0.00 | filing |
| 6 May 2026filed 7 May 2026 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Code M | $161K122,220 at $1.32 | filing |
| 6 May 2026filed 7 May 2026 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Code M | $47K44,444 at $1.05 | filing |
| 15 Jan 2026filed 16 Jan 2026 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 15 Jan 2026filed 16 Jan 2026 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 15 Jan 2026filed 16 Jan 2026 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 15 Jan 2026filed 16 Jan 2026 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 9 Jan 2026filed 12 Jan 2026 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Sold | $11K10,589 at $1.06 | filing |
| 9 Jan 2026filed 12 Jan 2026 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Sold | $11K10,589 at $1.06 | filing |
| 4 Aug 2025filed 5 Aug 2025 | FATE Fate TherapeuticsBiotechnology | SEC FORM 4 Sold | $9,5799,037 at $1.06 | filing |
| 15 Jan 2025filed 16 Jan 2025 | FATE Fate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —275,000 at $0.00 | filing |
News
Analyzing Fate Therapeutics (NASDAQ:FATE) & Applied Therapeutics (NASDAQ:APLT)FATE · dailypolitical.com · 19 Oct 2026
0 headlines in the last 90 days name Cindy Tahl; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.